Investigating the Economic Burden and Cost-effectiveness Evidence Base for Rare Kidney Diseases
Rare kidney diseases (RKD) place a substantial economic burden on patients and health systems, the extent of which is unknown and may be systematically underestimated by health economic techniques.
The “Scoping Review of Economic Analyses of Rare Kidney Diseases,” written in collaboration with The George Institute for Global Health, examines the existing evidence base toward building an investment case for RKD treatments.
The review is an ISN initiative. Funding for this research was provided by Novartis.
